Bronchiectasis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 15: Line 15:


====Treatment of Acute Exacerbations====
====Treatment of Acute Exacerbations====
*Exacerbations can be defined as patients reporting four or more of the following symptoms: change in sputum production, increased dyspnea, increased cough, fever over 38 °C, increased wheezing, decreased exercise tolerance, fatigue, malaise, lethargy, reduced pulmonary function, changes in chest sounds or radiographic changes consistent with a new infectious process
*Exacerbations can be defined as patients reporting four or more of the following symptoms: change in sputum production, increased dyspnea, increased cough, fever over 38 °C, increased wheezing, decreased exercise tolerance, fatigue, malaise, lethargy, reduced pulmonary function, changes in chest sounds or radiographic changes consistent with a new infectious process.


*The mainstay of treatment is antibiotic therapy.
*The mainstay of treatment is antibiotic therapy.
Line 49: Line 49:
*The combination of a long-acting beta2-agonists (LABA) with a conventional inhaled corticosteroids (IC) improved the quality of life.
*The combination of a long-acting beta2-agonists (LABA) with a conventional inhaled corticosteroids (IC) improved the quality of life.


===Physiotherapy Strategies===
== Physiotherapy Strategies===
====Airway Clearance====
====Airway Clearance====
*Postural Drainage
*Postural Drainage

Revision as of 15:28, 24 June 2015

Bronchiectasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Bronchiectasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bronchiectasis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bronchiectasis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bronchiectasis medical therapy

CDC on Bronchiectasis medical therapy

Bronchiectasis medical therapy in the news

Blogs on Bronchiectasis medical therapy

Directions to Hospitals Treating Bronchiectasis

Risk calculators and risk factors for Bronchiectasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The medical therapy is divided into medical treatment and physiologic strategies. The medical treatment consists of patient education, treatment of the acute exacerbations, prophylactic treatment, vaccination, and other therapies. The physiotherapy strategies focuses on airway clearance and pulmonary rehabilitation.


Bronchiectasis Medical Therapy

Medical Treatment

Patient Education

  • The patients should understand their diagnosis clearly.
  • Smoking cessation, regular exercise, and proper nutrition should be advised.
  • The patient should know how to self-manage acute exacerbations with a home supply of antibiotics.

Treatment of Acute Exacerbations

  • Exacerbations can be defined as patients reporting four or more of the following symptoms: change in sputum production, increased dyspnea, increased cough, fever over 38 °C, increased wheezing, decreased exercise tolerance, fatigue, malaise, lethargy, reduced pulmonary function, changes in chest sounds or radiographic changes consistent with a new infectious process.
  • The mainstay of treatment is antibiotic therapy.
  • Once the sputum specimen is collected and sent for culture, a targeted antibiotic therapy is recommended.
  • Colonization with a particular microorganism is graded as chronic if the same microorganism is detected in three or more consecutive cultures separated by at least 1 month over a period of 6 months.[1]
  • Oral antibiotic therapy should be used first line for 10-14 days. Intravenous (IV) antibiotics may be needed if there has been: no response to oral antimicrobials, systemic deterioration or if pathogenic organisms sensitive only to IV agents are cultured. [1]
  • Here are suggested antibiotics with specific culture growth
  • H. influenza type B
  • Amoxicillin 1 g tds × 2/52, Doxycycline 100 mg bd × 2/52
  • If β-lactamase-positive strain, Augmentin 625 mg tds × 2/52
  • P. aeruginosa
  • Ciprofloxacin 750 mg BD × 2/52
  • If no response or resistant to above, consider IV alternatives for 2/52: Ceftazidime 2 g tds × 2/52 IV, Tazocin 4.5 g tds IV or Meropenem 1 g tds IV
  • S. pneumoniae
  • Amoxicillin 1 g tds × 2/52
  • M. catarrhalis
  • Augmentin 625 mg tds × 2/52 or Ciprofloxacin 500 mg BD × 2/52
  • S. aureus
  • Flucloxacillin 1 g qds × 2/52

Prophylactic Treatment

  • National guidelines recommend that patients suffering from three or more exacerbations per year, should be considered for long-term antibiotics.[1]

Vaccination

  • There has been some evidence to support that the yearly influenza vaccine reduces morbidity, mortality, and healthcare costs with high-risk patients.

Other Therapies

  • Inhaled mannitol and nebulized hypertonic 7% saline have demonstrated effectiveness in increased airways clearance and sputum yield.[1]
  • Inhaled corticosteroids show a significant decrease in sputum production and cough.[1]
  • Macrolides exhibit anti-bacterial and immunomodulatory effects.[1]
  • The combination of a long-acting beta2-agonists (LABA) with a conventional inhaled corticosteroids (IC) improved the quality of life.

Physiotherapy Strategies=

Airway Clearance

  • Postural Drainage
  • Autogenic Drainage
  • Active Cycle of Breathing Techniques
  • Positive Expiratory Pressure (PEP)
  • Oscillatory PEP devices
  • High-frequency chest wall percussion

Pulmonary Rehabilitation

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 McDonnell MJ, Ward C, Lordan JL, Rutherford RM (2013). "Non-cystic fibrosis bronchiectasis". QJM. 106 (8): 709–15. doi:10.1093/qjmed/hct109. PMID 23728208.


Template:WikiDoc Sources